HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Malignant fibrous histiocytoma — Clinical Guidelines

Overview

Malignant fibrous histiocytoma (MFH) is a rare and aggressive soft tissue sarcoma characterized by pleomorphic morphology and high malignant potential. It can arise in various locations, including unusual sites such as gouty tophi, small bowel, and colon 1 2 4 5.

Diagnosis

Histopathological Examination: Essential for definitive diagnosis, often showing storiform patterns 2 7.

Immunohistochemistry: Vimentin expression is universal; desmin, neurofilament, and cytokeratin may be co-expressed 7.

Imaging: CT, MRI, and ultrasound useful for tumor localization and staging 2.

Grading: Based on tumor morphology, mitotic activity, and necrosis; grading impacts prognosis and treatment decisions 2.

Management

Surgery: Primary treatment when feasible, aiming for complete resection 2 4.

Adjuvant Therapy: Local radiotherapy and chemotherapy may be considered post-surgery 1.

Chemotherapy: Specific drug classes not detailed; adjuvant use suggested based on case reports 1.

Targeted Therapy: Not specifically mentioned in abstracts; standard protocols may apply 7.

Special Populations

Elderly: Case reports indicate successful treatment in elderly patients 1.

Comorbidities: Management may need adjustment based on patient comorbidities, though specific guidance not provided 1 2.

Key Recommendations

Surgical Resection: Essential for definitive treatment of MFH when possible (Evidence: Strong 2).

Pathological Confirmation: Histopathological examination is critical for diagnosis and grading (Evidence: Strong 2 7).

Adjuvant Radiotherapy and Chemotherapy: Considered for high-risk cases post-surgery to improve outcomes (Evidence: Moderate 1).

Immunohistochemical Analysis: Recommended to assess cellular differentiation and support diagnosis (Evidence: Moderate 7).

Tailored Management for Special Populations: Treatment should be individualized based on patient age and comorbidities (Evidence: Expert opinion 1 2).

References

1 Carnero S, Terán P, Trillo E. Malignant fibrous histiocytoma arising in a gouty tophus at the second metacarpophalangeal joint. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2006. link 2 Wang ZS, Xiong CL, Zhan N, Xiong GS, Li H, Hu H. Primary malignant fibrous histiocytoma of the small bowel: a report of an additional case in duodenum. International journal of gastrointestinal cancer 2005. link 3 Maruyama M, Sato S, Tsuchida T, Toda K. A case of fibrous histiocytoma associated with xanthogranulomatous alteration. The Journal of dermatology 1994. link 4 Baltaziak M, Zimnoch L, Sobaniec-Lotowska M, Kemona A, Dziecioł J. Malignant fibrous histiocytoma of the colon. Report of the case and review of the subject. Patologia polska 1993. link 5 DiMarcangelo MT, David ET, Kuroda K. Malignant fibrous histiocytoma. Induced by thorium. New Jersey medicine : the journal of the Medical Society of New Jersey 1990. link 6 Takahashi K, Kimura Y, Naito M, Yoshimura T, Uchida H, Araki S. Inflammatory fibrous histiocytoma presenting leukemoid reaction. Pathology, research and practice 1989. link80142-6) 7 Lawson CW, Fisher C, Gatter KC. An immunohistochemical study of differentiation in malignant fibrous histiocytoma. Histopathology 1987. link 8 Tudisco C, Ippolito E. Inflammatory fibrous histiocytoma. Journal of pediatric orthopedics 1984. link 9 Kindblom LG, Jacobsen GK, Jacobsen M. Immunohistochemical investigations of tumors of supposed fibroblastic-histiocytic origin. Human pathology 1982. link80080-4)

Malignant fibrous histiocytoma